A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects With Sickle-Cell Disease (SCD).

Trial Profile

A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects With Sickle-Cell Disease (SCD).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Sevuparin (Primary)
  • Indications Sickle cell anaemia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Modus Therapeutics
  • Most Recent Events

    • 05 Apr 2017 Planned number of patients changed from 120 to 133.
    • 05 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 05 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top